Page last updated: 2024-11-06

bis(diphenylphosphine)ethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Bis(diphenylphosphine)ethane, commonly known as DPPE, is a bidentate phosphine ligand widely used in coordination chemistry and organometallic catalysis. It is synthesized by the reaction of 1,2-dibromoethane with lithium diphenylphosphide. DPPE forms stable complexes with a variety of transition metals, including platinum, palladium, and nickel, which have found applications in various catalytic reactions. Its importance arises from its ability to stabilize and activate metal centers, promoting reactivity and selectivity in catalytic processes. The study of DPPE complexes is driven by their potential applications in areas such as organic synthesis, polymer chemistry, and pharmaceuticals. Notably, DPPE-based catalysts have shown remarkable activity and selectivity in reactions such as cross-coupling reactions, hydrogenation, and hydroformylation.'

Cross-References

ID SourceID
PubMed CID74267
CHEMBL ID68683
CHEBI ID30669
SCHEMBL ID27343
MeSH IDM0140808

Synonyms (65)

Synonym
AC-4965
bis(1,2-diphenylphosphino)ethane
ethane-1,2-diylbis(diphenylphosphane)
CHEBI:30669 ,
1,2-bis(diphenylphosphino)-ethane
phosphine, 1,2-ethanediylbis[diphenyl-
bis(diphenylphosphine)ethane
p,p'-ethylenebis(diphenylphosphine)
ethylenebis(diphenylphosphine)
1,2-bis(diphenylphosphino)ethane
1,2-bis(diphenylphosphine)ethane
phosphine,2-ethanediylbis[diphenyl-
diphos
1,2-ethanediylbis(diphenylphosphine)
nsc-76285
1663-45-2
nsc76285
phosphine, ethylenebis[diphenyl-
ethylenebis(diphenylphosphine), 97%
ethylenebis(diphenylphosphine), 99%
B1137 ,
CHEMBL68683
2-diphenylphosphanylethyl(diphenyl)phosphane
1,2-bis-(diphenylphosphino)ethane
2-(4-benzylphenoxy)-n,n-diethyl-ethanamine hydrochloride
A810721
AKOS004902197
kl33qe52i4 ,
phosphine, 1,2-ethanediylbis(diphenyl-
phosphine, 1,1'-(1,2-ethanediyl)bis(1,1-diphenyl-
nsc 76285
unii-kl33qe52i4
einecs 216-769-2
BP-12632
phosphine, [(diphenylphosphino)ethyl]diphenyl-
FT-0606310
GC10104
1,2-bis(diphenylphosphino)ethane (dppe)
EPITOPE ID:189315
1,2-bis (diphenyl)phosphinoethane
1,2-bis(diphenylphosphino) ethane
1,2-bis-(diphenylphosphino)-ethane
(c6h5)2pch2ch2p(c6h5)2
1,2-bis-diphenylphosphinoethane
1.2-bis-diphenylphosphinoethane
ph2pch2ch2pph2
1,2-bis(diphenyl-phosphino) ethane
SCHEMBL27343
mfcd00003047
SY004987
DTXSID2061858
dppe [mi]
ethanediylbis(diphenylphosphine)
Q-201094
FD14027
phosphine, 1,1'-(1,2-ethanediyl)bis[1,1-diphenyl-
[2-(diphenylphosphino)ethyl](diphenyl)phosphine #
CS-W008662
[2-(diphenylphosphanyl)ethyl]diphenylphosphane
F0001-0605
BCP22570
1,2-bis(diphenylphosphor)ethane
Q161453
AMY19693
EN300-54087
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tertiary phosphineA compound derived from phosphane by substituting three hydrogen atoms by hydrocarbyl groups.
diphosphanesCompounds containing two phosphane groups linked directly by a P-P bond or via a hydrocarbon bridge.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID221998Tumor growth inhibition activity after subcutaneous transplanted tumor in mammary carcinoma 16/C cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID103458Percent increase in life span after transplant tumor in Lewis lung carcinoma cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID115142Maximally tolerated dose was measured after ip administration of compound, 24 hr after tumor implantation.1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID38071In vitro cytotoxicity against murine B16 melanoma cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID153809Maximum increase in life span was determined against P388 leukemia at 4-5 doses of compound1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID10059Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID248395Inhibitory concentration against human lung carcinoma cell line H460 after 48 hr in MTT assay2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
Mechanism of cytotoxicity of copper(I) complexes of 1,2-bis(diphenylphosphino)ethane.
AID38081Percent increase in life span after transplant tumor in B16 melanoma cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID101218Percent increase in life span after transplant tumor in L1210 leukemia1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID102067Percent increase in life span after transplant tumor in M5076 reticulum cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID153795Percent increase in life span after transplant tumor in p388 leukemia cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
AID106646Percent increase in life span after transplant tumor in Madison lung carcinoma cells1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's1 (6.67)18.2507
2000's5 (33.33)29.6817
2010's6 (40.00)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.29 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]